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Abstract: More than three million Americans have chronic hepatitis C infection, and the disease 
remains one of the most common blood-borne infections in the US. Treatment is focused on the 
chronic form of the disease, because the acute one tends to be self-limiting. In this article, we 
review the recent literature regarding the most effective therapy against hepatitis C infection, to 
confirm the current treatment of choice for the disease. We conclude that combination therapy 
with pegylated interferon and ribavirin remains the initial treatment of choice. New research 
focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early 
data that appear to be promising.
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Introduction
Chronic hepatitis C (HCV) infection continues to be one of the most common blood-
borne infections, accounting for approximately 40% of all chronic liver disease.1,2 Up to 
20% of all HCV-infected individuals develop liver cirrhosis and are at increased risk of 
developing hepatocellular carcinoma (HCC). Chronic hepatitis C infection also remains 
the leading cause of liver transplantation in the US. The Centers for Disease Control 
(CDC) estimates that approximately 3.2 million Americans are infected with chronic 
hepatitis C, and that an estimated 8000 to 10,000 deaths occur each year because of the 
disease.1 In 2007, 849 cases of confirmed acute hepatitis C infection were reported in 
the US but the CDC estimates that approximately 17,000 new HCV infections occurred 
that year, after adjusting for asymptomatic infection and underreporting.1
Since the discovery of the virus in 1989, attention has focused on treating the 
chronic form of the infection. Acute hepatitis C is a self-limiting process, but leads to 
the chronic form of the disease in 75%–85% of cases.3
We reviewed the recent literature regarding the most effective therapy for HCV , as 
well as the current guidelines from the American Association for the Study of Liver 
Disease (AASLD), National Institutes of Health (NIH), and the CDC to confirm the 
present treatment of choice for chronic hepatitis C infection.
The consensus remains that initial combination therapy using pegylated interferon 
and ribavirin is superior to combination therapy of standard interferon and ribavirin 
or interferon monotherapy.3,4,5 Decisions about who to treat, duration of treatment, 
and what drugs to use are affected by many factors, including the genotype of the 
virus, nature and degree of aminotransferase abnormalities, and characteristics seen 
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Current research regarding the treatment of chronic HCV 
is focusing on protease inhibitors that interrupt the viral rep-
lication cycle. Some protease and polymerase inhibitors have 
already advanced into clinical trials evaluating their ability 
to achieve a sustained viral response (SVR), defined as the 
absence of HCV RNA in serum at the end of treatment and 
six months later. Initial data appear to be promising.6
Role of liver biopsy
The role of liver biopsy continues to be a controversial topic 
in the management of chronic hepatitis C. A biopsy reveals 
important information about the degree of hepatic inflamma-
tion, staging of fibrosis, and histopathologic features. Most 
clinicians still perform a biopsy prior to the initiation of treat-
ment because of its many practical advantages. The AASLD 
recommends that regardless of the alanine transaminase (ALT) 
level, a liver biopsy should be performed when the results will 
influence whether treatment is recommended, but at the same 
time, a biopsy is not mandatory in order to initiate therapy.4,7 
In patients with genotype 1, a liver biopsy is usually helpful in 
deciding whether or not to start treatment. In other cases, such 
as infection with genotypes 2 or 3, given the high likelihood 
of response to treatment, one could argue that there is no need 
for liver biopsy. A baseline liver biopsy may be helpful in mak-
ing decisions if patients experience medication side effects 
and adjustment of treatment is necessary. In addition, a liver 
biopsy can be used to rule out other liver diseases in the initial 
workup of patients infected with chronic HCV .4 Steatosis and 
excess hepatocellular iron levels are two common liver biopsy 
findings that can impede a treatment response. Having one or 
both of these findings on biopsy is not a contraindication to 
initiate treatment, but their presence might help in predicting 
response to treatment.4
HCV genotyping
As part of the initial workup, all patients with chronic HCV 
infection should undergo testing to investigate the viral geno-
type. Genotyping is important in predicting the response to 
treatment, as well as determining the duration of treatment.11 
HCV is an RNA virus with six known genotypes and more 
than 50 subtypes.8,9,10 Genotype 1 is the most common HCV 
genotype in the US and accounts for three-quarters of all 
HCV infections, and remains the most difficult type to treat. 
Genotypes 2 and 3 account for most of the other genotypes 
in the US, and genotype 4 remains prevalent in Egypt. Once 
the genotype is identified, there is no value in rechecking 
it, because the likelihood of coinfection with multiple 
genotypes is rare.
Goals of treatment
The majority of patients acutely infected with HCV are either 
asymptomatic or develop mild symptoms such as fevers, 
fatigue, joint pain, nausea, and vomiting, and therefore do not 
seek medical attention. However, 75%–85% of those infected 
with acute hepatitis C will remain HCV-infected, with the 
majority also developing chronic liver disease.3 Up to 20% of 
chronic HCV-infected patients are reported to develop cirrhosis 
over a period of 20–30 years. It is because of the cirrhosis, and 
the more feared complication of HCC, as well as other intra- 
and extrahepatic manifestations of chronic HCV infection, 
that treatment is recommended for most patients with HCV 
infection. The goal of treatment is eradication of the virus to 
prevent the complications associated with the disease.4
Ribavirin monotherapy
Ribavirin is a nucleoside analog that inhibits replication of 
RNA viruses by inhibiting the initiation and elongation of 
RNA fragments, resulting in inhibition of viral protein syn-
thesis. Ribavirin appears to inhibit hepatitis C viral infectivity 
in a dose-dependent manner.11 Several trials have evaluated 
the use of ribavirin as monotherapy for chronic hepatitis C 
infection. Brok et al performed a meta-analysis of 11 trials 
and concluded that, when used alone, ribavirin is ineffec-
tive in achieving an SVR, and patients who are intolerant 
of interferon should not continue treatment with ribavirin   
alone.11
In a randomized, double-blind, placebo-controlled trial 
by Di Bisceglie et al, 58 patients were randomly assigned to 
receive oral ribavirin or placebo for one year. They found that 
ribavirin had beneficial effects on serum aminotransferase 
levels and histologic findings on liver biopsy in patients with 
chronic hepatitis C infection. However, these effects were 
not accompanied by changes in HCV RNA levels, and were 
not sustained when ribavirin therapy was discontinued.12,13 
Thus, when used alone, even for periods as long as one 
year, ribavirin is unlikely to be of value as monotherapy for 
chronic hepatitis C.
Pegylated versus regular  
interferon monotherapy
Pegylation of interferon, ie, the covalent attachment of poly-
ethylene glycol polymer chains to another molecule, in this 
case interferon, results in an increase in the hydrodynamic 
size of the drug which, in turn, prolongs its circulatory time 
by reducing renal clearance, and decreases the immunogenic-
ity of the drug. There are two forms of peginterferon approved 
by the Food and Drug Administration (FDA) in the US, Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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ie, the 40 kDa peginterferon alfa-2a (Pegasys®, Hoffmann-La 
Roche, Nutley, NJ) and 12 kDa peginterferon alfa-2b (Peg-
Intron®, Schering-Plough Corporation, Kenilworth, NJ).
When used as monotherapy, interferon (whether pegylated 
or not), has better outcomes than ribavirin alone. Peginterferon 
monotherapy is associated with higher rates of SVR compared 
with standard interferon.14 SVR rates are ∼25% for patients 
with HCV genotype 1 (compared with 8%–12% with stan-
dard interferon) and 54% for those with genotypes 2 and 3 
(compared with ∼34% for standard interferon).
Multiple studies were done to compare treatment of HCV 
using nonpegylated interferon versus the pegylated form of 
the drug.9,10,14 These studies revealed that peginterferon is 
superior to and as safe as interferon for the initial treatment 
of adult patients with compensated chronic hepatitis C. 
In a randomized, double-blind trial comparing pegylated 
interferon alfa-2b with standard interferon alfa-2b, patients 
were randomly assigned to one of four treatment groups.14 
Three groups were treated with peginterferon alfa-2b (0.5, 
1.0, or 1.5 µg/kg subcutaneously once weekly) and one 
group was treated with standard interferon alfa-2b (3 MU 
subcutaneously three times per week). The results of the 
study revealed that the end-of-treatment viral response for 
peginterferon alfa-2b was dose-related. An increase in the 
dose of peginterferon alfa-2b (0.5, 1.0, and 1.5 µg/kg) was 
associated with an increase in the viral response rate (33%, 
41%, and 49%, respectively). All three peginterferon alfa-2b 
dose groups had significantly higher proportions (P , 0.01) 
of patients with an end-of-treatment viral response compared 
with the standard interferon alfa-2b group (24%).14
While combination therapy with peginterferon and ribavi-
rin remains the optimal initial treatment for HCV patients as 
detailed below, there are certain populations in which treat-
ment with ribavirin is contraindicated, leaving peginterferon 
monotherapy as the primary choice of treatment.3 Such is true 
in patients with renal disease, especially those requiring hemo-
dialysis. Ribavirin is not recommended for patients who have 
a creatinine clearance below 50 mL/min. Ribavirin is also not 
cleared by dialysis, and in those individuals with end-stage renal 
disease the drug may accumulate and cause dose-dependent 
hemolytic anemia. Initial pilot studies have indicated that riba-
virin can cause severe hemolysis, and a number of other small 
studies have indicated that ribavirin levels have to be monitored 
very closely if used in this subpopulation.
Combination therapy
Combination therapy of peginterferon alfa and ribavirin 
continues to be the optimal initial treatment for HCV on the 
basis of the findings of three major trials (see Figure 1). The 
first trial, carried out by Manns et al included 1530 patients 
with chronic hepatitis C who were assigned to one of three 
treatment arms.15 The first arm received interferon alfa-2b 
(3 MU subcutaneously three times per week) and ribavirin 
1000–1200 mg/day. The second arm received peginterferon 
alfa-2b (1.5 µg/kg/week) and 800 mg/day ribavirin, while the 
third arm received peginterferon alfa-2b (1.5 µg/kg/week for 
four weeks then 0.5 µg/kg/week) and ribavirin 1000–1200 
mg/day, for a total of 48 weeks. The results of this trial showed 
that the SVR rate was significantly higher in the higher-dose 
peginterferon group (54%) than in the lower-dose peginter-
feron (47%) or interferon (47%) groups. Among patients 
with HCV genotype 1 infection, the corresponding SVR rates 
were 42%, 34%, and 33%. The SVR rate for patients with 
genotypes 2 and 3 infection was about 80% for all treatment 
groups. This demonstrated that the most effective therapy is 
the combination of peginterferon alfa-2b 1.5 µg/kg/week and 
ribavirin, with the most benefit seen in patients with HCV 
genotype 1 infection. In addition, the study found that the 
side effects seen with the peginterferon alfa-2b and ribavirin 
combination were similar to those with interferon alfa-2b 
and ribavirin. There was an increase in influenza-like effects 
with the peginterferon, although the authors related that to 
the higher dose of peginterferon used in the trial.
The second trial by Fried et al was a multicenter study 
that involved 1121 patients who were randomly assigned 
to one of three treatment groups.16 One group received 
combined treatment with peginterferon alfa-2a 180 µg once 
per week and ribavirin 1000–1200 mg/day. The second 
group received peginterferon alfa-2a 180 µg once per week 
and placebo (peginterferon alfa-2a monotherapy). The third 
group received interferon alfa-2b (3 MU subcutaneously 
three times per week) and ribavirin 1000–1200 mg/day. The 
treatment duration was 48 weeks.
As with the combination therapy trial involving peginter-
feron alfa-2b and ribavirin, this study also found that a higher 
rate of SVR was achieved in patients who received peginter-
feron alfa-2a and ribavirin than in those who received inter-
feron alfa-2b and ribavirin (56% versus 44%, respectively) 
or peginterferon alfa-2a monotherapy (56% versus 29%).
The third investigation was a randomized, double-blind, 
multicenter trial by Hadziyannis et al who evaluated 1311 
patients with chronic hepatitis C, with the objective of 
assessing the efficacy and safety of 24 versus 48 weeks of 
combination treatment with peginterferon alfa-2a (180 µg 
per week) and ribavirin at a low dose (800 mg/day) or 
as a standard weight-based dose (1000–1200 mg/day).17 Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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The study found that, overall, in patients infected with HCV 
genotype 1, treatment for 48 weeks was statistically supe-
rior to that for 24 weeks, and that standard-dose ribavirin 
(1000–1200 mg/day) was statistically superior to low-dose 
ribavirin. However, the trial also found that in patients 
with HCV genotypes 2 and 3, the SVR was not statisti-
cally different in any of the treatment groups. Based on the 
results of this study, the current recommended treatment 
for patient with chronic hepatitis C infection genotype 2 or 
3 is peginterferon with lower-dose ribavirin (800 mg/day) 
for 24 weeks only.
Peginterferon alfa-2a versus 
peginterferon alfa-2b
The few head-to-head comparisons done thus far for the two 
forms of pegylated interferon have found that SVR rates are 
not significantly different. In the COMPARE trial, Silva et al 
randomized 36 patients to two treatment groups, one receiv-
ing peginterferon alfa-2b (1.5 µg/kg/week) and the other 
receiving peginterferon alfa-2a (180 µg/week) for four weeks, 
and then added ribavirin (13 mg/kg/day) for an additional 
four weeks to each group.18 The pharmacokinetic profile, 
mRNA expression of interferon-induced gene transcripts, 
and HCV RNA levels, were measured. The study results 
showed that patients treated with peginterferon alfa-2b had 
a greater upregulation of peginterferon alfa response genes 
and a greater decrease in HCV RNA measured at one and 
four weeks than patients receiving peginterferon alfa-2a. 
However, the study did not include measurement of the SVR 
for each group, and the duration of treatment was not the 
recommended 48 weeks.
A study by Di Bisceglie et al compared the two forms of 
the drug.19 In this randomized, prospective, open-label trial, 
380 patients infected with HCV genotype 1 with high viral 
loads were allocated to one of two treatment arms. One arm 
received peginterferon alfa-2a (180 µg/week) and ribavirin 
1000–1200 mg, while the other arm received peginterferon 
alfa-2b (1.5 µg/kg/week) and ribavirin 1000–1200 mg for 
12 weeks. Drug levels were measured before treatment and 
weekly during the first week through to week 12. The viral 
response was also measured at week 12 and at the end of the 
study. HCV RNA levels were comparable between the two 
groups, with no significant difference at any point in time 
during the study. The proportion of patients with an early 
Figure 1 Likelihood of achieving a sustained viral response with different modalities of treatment, for hepatitis C virus genotype 1 and genotypes 2 and 3.
Abbreviation: SvR, sustained viral response.
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viral response (EVR) was similar between the two arms 
(66% versus 63%, respectively). In addition, there was no 
difference between the groups for those with a rapid viral 
response (RVR), defined as an undetectable serum HCV 
RNA level after four weeks of treatment. The investigators 
concluded that the two peginterferon preparations showed 
comparable anti-HCV activity during the first 12 weeks of   
treatment.
A third trial compared the same two drug formulations 
in the treatment of HCV infection in a subpopulation of 
patients coinfected with HIV , and the results again showed 
no significant differences in the efficacy and safety of the 
two forms of the drug.20
In a more recent study by McHutchison et al involving 118 
centers, 3070 patients infected with HCV genotype 1 were 
randomly assigned to one of three treatment groups.21 The 
first group was treated with a combination of peginterferon 
alfa-2b at a standard dose of 1.5 µg/kg/week and ribavirin at 
a dose of 800–1400 mg/day. The second group was treated 
with peginterferon alfa-2b at a low dose of 1.0 µg/kg/
week and ribavirin 800–1400 mg/day. The third group was 
treated with peginterferon alfa-2a 180 µg/week and ribavirin 
1000–1200 mg/day. Each of the three groups completed 48 
weeks of treatment. The investigators compared SVR rates 
and the safety profiles of the peginterferon alfa-2b regimens 
and the standard-dose peginterferon alfa-2a and peginter-
feron alfa-2b regimens. SVR rates were similar for the three 
regimens, ie, 39.8% for standard-dose peginterferon alfa-2b, 
38.0% for low-dose peginterferon alfa-2b, and 40.9% for 
peginterferon alfa-2a (P = 0.20 for standard dose versus 
low-dose peginterferon alfa-2b; P = 0.57 for standard-dose 
peginterferon alfa-2b versus peginterferon alfa-2a). In addi-
tion, McHutchison et al reported that the safety profile was 
similar among the three groups. The study concluded that 
in patients infected with the HCV genotype 1, SVR and 
tolerability rates did not differ significantly between the two 
available peginterferon-ribavirin regimens or between the 
two doses of peginterferon alfa-2b.21
Another recent study by Ascione et al revealed a differ-
ence between the two forms of peginterferon in 320 con-
secutive, treatment-naive, HCV RNA-positive patients with 
chronic hepatitis. They randomly assigned these patients to 
once-weekly peginterferon alfa-2a (180 µg, Group A) or 
peginterferon alfa-2b (1.5 µg/kg, Group B) and ribavirin 
1000 mg/day (body weight , 75 kg) or 1200 mg/day (body 
weight . 75 kg) for 48 weeks (genotypes 1 and 4) or 24 
weeks (genotypes 2 and 3.) The primary endpoint was SVR. 
More patients in Group A than Group B achieved an SVR 
(110/160 [68.8%] versus 87/160 [54.4%]; P = 0.008), with 
baseline HCV RNA levels . 500,000 IU/mL (58/84 [69%] 
versus 43/93 [46.2%]; P = 0.002). However, the SVR rates 
in groups A and B were not statistically different in patients 
with baseline HCV RNA , 500,000 IU/mL (52/76 [68.4%] 
versus 44/67 [65.7%]; P = 0.727) or in patients with cirrhosis 
(14/33 [42.4%] versus 12/26 [46.1%]; P = 0.774).22
Predictors of treatment response
Several pretreatment characteristics, as well as an early 
response to treatment, contribute to the likelihood of 
eradicating HCV infection and achieving an SVR. The viral 
genotype continues to be one of the strongest predictors 
of response.4,5,23 Patients infected with HCV genotype 1, 
which is the most common genotype in the US, continue to 
be those in whom an SVR is most difficult to achieve and 
who require the longest duration of treatment. On the other 
hand, those with genotypes 2 or 3 tend to have an EVR and 
should be treated with a combination of peginterferon and 
lower-dose ribavirin for a period of 24 weeks only.
Lower pretreatment HCV RNA levels (less than two 
million copies per mL) also correlate with better SVR rates.21 
In addition, age younger than 40 years, absence of bridging 
fibrosis or cirrhosis on liver biopsy, absence of steatosis, and 
body weight less than 75 kg were all favorable pretreatment 
characteristics for achieving an SVR.24,25
More recent studies have been investigating whether 
RVR, defined as the absence of HCV RNA after four 
weeks of treatment with peginterferon and ribavirin, can 
be used as a marker to determine the duration of treat-
ment. A retrospective analysis of data from the trial by 
Hadziyannis et al showed that if an RVR is achieved, the 
likelihood of achieving an SVR was 89%–90% at both 
24 and 48 weeks of treatment.17 In a second prospective 
study, Ferenci et al investigated whether the same applies 
for HCV genotypes 1 and 4.26 Patients in this study received 
a combination of peginterferon alfa-2a 180 µg/week and 
ribavirin 1000–1200 mg/day. The patients who achieved 
an RVR by week 4 were assigned to complete 24 weeks of 
treatment. Of 516 patients included in the study, 150 had 
an RVR and 143 completed the 24 weeks of treatment. The 
study found that patients who achieved an RVR differed 
significantly from those without an RVR, in that patients 
with RVR were leaner, had lower pretreatment HCV RNA 
levels, and had lower baseline ALT levels. The study also 
showed that patients with genotype 1 or 4, who achieved 
an RVR, had an overall SVR of 80.4% after only 24 weeks 
of treatment.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
16
Yasin et al
Retreatment of nonresponders  
and relapsers
There are no clear guidelines regarding retreatment of 
patients who either never achieve an SVR (nonresponders) 
or those who relapse after an initial response to treatment. 
The approach to these patients should depend on the type of 
initial treatment they received, their previous type of response 
to that treatment, their viral genotype, and the severity of 
underlying liver disease. The AASLD recommends retreat-
ment with a combination of peginterferon and ribavirin for 
nonresponders or relapsers who have significant fibrosis 
or compensated cirrhosis, and who have undergone previ-
ous regimens of treatment using nonpegylated interferon.4 
However, for those patients who have failed to respond to 
the pegylated interferon and ribavirin combination regimen, 
retreatment to eradicate the disease is not recommended, even 
if a different type of pegylated interferon is used.
Krawitt et al investigated 182 patients who had previously 
failed to achieve an SVR at 24 weeks following a multiweek 
course of treatment with either interferon monotherapy or 
interferon in combination with ribavirin, and were then treated 
with a combination of pegylated interferon alfa-2b (100 µg/
week for those of body weight , 75 kg and 150 µg/week for 
those of body weight . 75 kg) and ribavirin 1000 mg/day.27 
The patients were treated for 24 weeks, at which time an HCV 
RNA level was measured. If the HCV RNA levels were unde-
tectable, treatment was continued for 24 more weeks for a total 
of 48 weeks. If HCV RNA levels were detectable, treatment 
was discontinued. The results of this study showed that SVR 
was achieved in 20% of previous nonresponders and 55% of 
previous relapsers. Within the previous nonresponders group, 
the SVR of those with genotype 1 was 17% compared with 
57% in those with genotypes 2 or 3, although this difference 
was not statistically significant.27 The study concluded that 
the response to the combination of pegylated interferon and 
ribavirin in previous nonresponders with genotypes 2 and 3 
and in prior relapsers is comparable with the overall rates of 
SVR in previously untreated patients.
Special populations
Of all the HIV-infected individuals worldwide, 25%–30% 
have chronic HCV coinfection. The consequences of such 
coinfection include accelerated progression of liver disease, 
higher rates of morbidity and mortality, and shortened lifespan 
following hepatic decompensation.28 Factors contributing to 
such deleterious consequences include higher HCV viral 
loads and possibly replication of HCV at extrahepatic sites, 
including in dendritic cells, peripheral blood mononuclear 
cells, and monocytes.29 Therefore, HCV/HIV coinfected 
patients present challenging issues for treatment.
One of the first decisions to be addressed in the coinfected 
individual is which infection should be treated first. That usu-
ally depends on the relative stage of each disease.28 In those 
individuals who do not require antiretroviral therapy for HIV , 
treatment of HCV should be the first priority.30 However, in 
individuals with AIDS and CD4 counts , 200, antiretroviral 
therapy and prophylaxis should be started first. HCV treat-
ment should be initiated when the CD4 counts recover. In 
patients with a history of recurrent drug-induced hepatotox-
icity and an inability to tolerate antiretroviral therapy, HCV 
treatment should be initiated first.
The primary goal of therapy in HIV/HCV coinfected 
patients remains the same as for those with HCV infec-
tion, ie, achieving an SVR. Secondary goals of treatment 
include reducing fibrosis and necroinflammatory activity.28 
The treatment of choice for such individuals remains the 
combination of pegylated interferon and ribavirin. In the 
AIDS Pegasys Ribavirin International Coinfection Trial 
(APRICOT), Torriani et al showed that patients treated with 
the combination of peginterferon alfa-2a and ribavirin had 
an SVR of 40% compared with 20% in those treated with a 
combination of peginterferon alfa-2a and placebo and 12% 
in those who received a combination of standard interferon 
and ribavirin.31
Some studies have shown that 3-hydroxy-3-methylglutaryl-
coenzyme A (HMC-CoA) reductase inhibitors play a role in 
in vitro HCV viral replication. Milazzo et al have published 
results of a randomized, open-label study in which 44 patients 
coinfected with HIV/HCV were randomized to receive 
either a peginterferon alfa-2b and ribavirin combination or 
a triple combination of peginterferon alfa-2b, ribavirin, and 
fluvastatin. The primary endpoint of the study was SVR and 
the secondary endpoint was RVR. The results of this study 
revealed that addition of fluvastatin to standard therapy did 
not significantly increase SVR rates but did significantly 
improve RVR rates.32
Another special population of HCV-infected individuals is 
those using illicit intravenous drugs. According to the AASLD, 
decisions regarding HCV treatment in this group should be 
made on a case-by-case basis, considering the anticipated risks 
and benefits. Treatment should not be withheld from persons 
who currently use illicit drugs or who are on a methadone 
maintenance program, provided that they are able and willing 
to maintain close monitoring and practice contraception.4
In addition, the AASLD reports that antiviral treatment is 
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recipients, those with uncontrolled major depressive disorder, 
autoimmune hepatitis, or other conditions that might be 
exacerbated by interferon and ribavirin, and those who are 
pregnant, or are unwilling or unable to practice adequate 
contraception.4
Side effects
Side effects of treatment of chronic hepatitis C infection 
remain a major reason of discontinuation, and drug intoler-
ance is an important factor in noncompliance with treat-
ment. Side effects occur in .20% of patients treated with 
pegylated interferon and ribavirin. Hematologic side effects 
are common, and include significant anemia, the cause of 
which is thought to be multifactorial, including bone marrow 
suppression from the interferon as well as ribavirin-induced 
hemolysis. The side effects of ribavirin seem to be dose-
related, because the drug is concentrated in red blood cells 
resulting in a relative deficiency of adenosine triphosphate in 
erythrocytes, which increases their susceptibility to oxidative 
damage and hemolysis.
Interferon can affect the bone marrow and may lead 
to suppression, neutropenia, and thrombocytopenia. This 
becomes significant especially when dealing with cirrhotic 
patients who have underlying thrombocytopenia secondary to 
liver disease. Other side effects of interferon include fevers, 
headaches, arthralgias, myalgias, fatigue, and rigors, all of 
which tend to occur in the first few weeks of treatment and 
improve as treatment continues. Decreased appetite, weight 
loss, alopecia, and insomnia have also been described as side 
effects of interferon.
Depression and other neuropsychiatric side effects, such 
as apathy and irritability, can be seen in up to 20% of patients 
treated with interferon. Suicide has also been reported in 
some patients treated with interferon and the AASLD now 
considers uncontrolled major depressive disorder as a con-
traindication to treatment.4
In a prospective case-control study, Huang et al recruited 
70 patients with chronic HCV who were $65 years of age for 
active treatment (Group A) and an additional 140 sex- and 
HCV genotype-matched patients who were 50–64 years of 
age as a control group (Group B). All patients were allo-
cated to receive a combination of peginterferon alfa-2a and 
ribavirin, with SVR as the primary endpoint. Patients were 
also monitored biweekly at outpatient visits during the first 
month, and then monthly thereafter for evaluation of drug 
safety. In addition, biochemical and hematologic tests were 
performed. Adverse events were graded as mild, moderate, 
severe, or potentially life-threatening. Group A was found to 
have a significantly higher rate of treatment discontinuation 
(21.4% versus 6.4%; P = 0.001) and adverse events (34.3% 
versus 20%; P = 0.002) than Group B. In addition, SVR rate 
was substantially lower in Group A than in Group B. There-
fore, in this study, older patients with HCV infection had a 
greater frequency of adverse events and poorer adherence to 
peginterferon and ribavirin.33
Future of HCV treatment
Current research on treatment for chronic HCV is focused on 
the protease inhibitors.6 Protease and polymerase inhibitors 
interrupt the cycle of viral replication. Some protease and poly-
merase inhibitors have already advanced into clinical trials for 
evaluation of their effect on achieving an SVR. Initial studies 
are showing that, when used in combination with the pegylated 
interferon and ribavirin, there is the potential to achieve an SVR 
in up to 70% of individuals with HCV genotype 1 infection 
compared with the current likelihood of achieving an SVR of 
50% with combination therapy alone.34
Summary
The goal of treatment for chronic hepatitis C infection is 
eradication of the virus to prevent its complications, includ-
ing chronic liver disease, cirrhosis, HCC, and extrahepatic 
manifestations. Eradication of the disease is measured by the 
SVR. Predictors of achieving an SVR are the viral genotype 
(with genotype 2 and 3 having a better prognosis than geno-
type 1), low HVC RNA load (less than two million copies/
mL), age younger than 40 years, absence of bridging fibrosis 
or cirrhosis on liver biopsy, absence of steatosis, and body 
weight less than 75 kg.
The current treatment of choice for chronic HCV infection 
is a combination of pegylated interferon alfa and ribavirin. The 
RVR as well as the EVR can be used to predict the likelihood 
of achieving an SVR once treatment is initiated. The current 
recommended duration of treatment for patients infected with 
the HCV genotype 1 is 48 weeks. If patients do not achieve an 
EVR, the recommendation would then be to stop treatment. For 
patients infected with HCV genotype 2 or 3, the recommended 
duration of treatment is 24 weeks rather than 48 weeks, and 
a lower dose of ribavirin can be used. Retreatment of nonre-
sponders and relapsers should depend on the initial medication 
regimen, the previous response to that treatment, viral geno-
type, and the severity of the underlying liver disease.
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